Ipsen has outlaid €700m ($798.4m) to acquire rare disease specialist Memo Therapeutics – enriching its pipeline with a mid-stage clinical asset.
As part of the takeover, the Paris, France-based pharma will pay Memo’s shareholders €200m at transaction close, which is expected in the third quarter of 2026. On top of this initial sum, Ipsen has pledged to allocate “in excess of €700m” to shareholders, provided Memo’s BK polyomavirus-targeting antibody reaches specific development, regulatory and sales-based payments.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The jewel in Memo’s crown is its lead asset, potravitug, which the company has engineered to treat BK polyomavirus associated nephropathy (BKPyVAN) – a serious kidney complication caused by the reactivation of a dormant childhood virus in patients with weakened immune systems. It most commonly impacts individuals who have had a kidney transplant, as anti-organ rejection drugs can weaken the immune system and allow the virus to become active.
US and European regulators granted Potravitug fast-track and orphan designations in 2023 and 2025 respectively. Memo plans to initiate its pivotal Phase III programme on potravitug, dubbed SAFE KIDNEY III, later this year. The drug acts by binding to the BK virus’ VP1 capsid protein, which is key to the virus’s ability to attach to and enter the cell. By suppressing this capacity, potravitug can prevent host cell infection and viral replication – preventing kidney damage these factors can cause.
Ipsen’s acquisition of Memo comes just days after the company announced the $1.75bn takeover of blood cancer drug developer, Kartos Therapeutics. The French pharma company secured the rights to Kartos’ Phase III drug through this buyout. Kartos designed the drug, dubbed navtemadlin, to improve on treatment with JAK inhibitor, Jakafi (ruxolitinib), in myelofibrosis.
Potravitug’s first-to-market potential
As Memo progresses potravitug in BKPyVAN, the company points to positive data obtained on the drug thus far in clinical trials, with a specific focus on the results of the US-based Phase II SAFE Kidney II study (NCT05769582).
During the trial, potravitug allowed significantly more patients to achieve lower or undetectable viral loads over placebo.
If the drug were to secure approval in BKPyVAN, it would become the first targeted therapy to reach patients in this indication.
According to Darshana Dadhania, medical director of the Kidney and Pancreas Transplant Program at Weill Cornell Medicine, BKPyVAN represents a “significant clinical challenge” within the kidney transplant recipient population. This is because clinicians are currently forced to reduce immunosuppressant regimens in affected patients – putting them at risk of graft rejection and loss.
“Given the frequency and serious consequences of BK virus reactivation, there remains an urgent need for effective therapy that avoids this trade-off,” Dadhania said.
